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ATP-binding-cassette-transporter-A1 (ABCA1) plays a pivotal role in intracellular cholesterol removal, exert-
ing a protective effect against atherosclerosis. ABCA1 gene severe mutations underlie Tangier disease, a rare
Mendelian disorder that can lead to premature coronary artery disease (CAD), with age of CAD onset being
two decades earlier in mutant homozygotes and one decade earlier in heterozygotes than in mutation non-
carriers. It is unknown whether common polymorphisms in ABCA1 could influence age of symptom onset
of CAD in the general population. We examined common promoter and non-synonymous coding polymorph-
isms in relation to age of symptom onset in a group of CAD patients (n 5 1164), and also carried out in vitro
assays to test effects of the promoter variations on ABCA1 promoter transcriptional activity and effects of the
coding variations on ABCA1 function in mediating cellular cholesterol efflux. Age of symptom onset was
found to be associated with the promoter 2407G>C polymorphism, being 2.82 years higher in C allele homo-
zygotes than in G allele homozygotes and intermediate in heterozygotes (61.54, 59.79 and 58.72 years,
respectively; P 5 0.002). In agreement, patients carrying ABCA1 haplotypes containing the 2407C allele
had higher age of symptom onset. Patients of the G/G or G/C genotype of the 2407G>C polymorphism
had significant coronary artery stenosis (>75%) at a younger age than those of the C/C genotype
(P 5 0.003). Reporter gene assays showed that ABCA1 haplotypes bearing the 2407C allele had higher pro-
moter activity than haplotypes with the 2407G allele. Functional analyses of the coding polymorphisms
showed an effect of the V825I substitution on ABCA1 function, with the 825I variant having higher activity
in mediating cholesterol efflux than the wild-type (825V). A trend towards higher symptom onset age in
825I allele carriers was observed. The data indicate an influence of common ABCA1 functional polymorph-
isms on age of symptom onset in CAD patients.
INTRODUCTION
ATP-binding-cassette-transporter-A1 (ABCA1) mediates
transport of intracellular cholesterol and phospholipids
across cell membranes where these lipid molecules are removed
from cells by apolipoprotein AI and other apolipoproteins
of nascent high-density lipoprotein (HDL), although the
mechanisms by which ABCA1 mediates lipid export is still
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incompletely understood (1,2). This process plays an import-
ant role in maintaining cellular cholesterol homeostasis and
exerts a protective effect against atherosclerosis (1–3).
Loss-of-functionmutations in theABCA1 gene cause Tangier
disease, a rare genetic disorder characterized by near absence of
HDL and accumulation of lipids within cells in various tissues
including the blood vessel wall (4–6). ABCA1mutation carriers
have markedly higher incidence of coronary artery disease
(CAD) compared with non-carriers (7). In addition, in families
of Tangier disease patients, onset of CAD is significantly earlier
in mutation carriers than in non-carriers (8,9). Increased inci-
dence of early onset CAD in ABCA1 mutation carriers is
likely attributed to the accumulation of lipid-laden macrophage
foam cells in the vascular wall, which would promote develop-
ment and progression of atherosclerosis (1–3).
Common single nucleotide polymorphisms (SNPs) in
ABCA1 have been associated with susceptibility to CAD in
the general population (10–16). In this study, we investigated
whether common promoter and non-synonymous coding SNPs
in ABCA1 have an influence on age of symptom onset in CAD
patients. In addition, we tested whether the promoter SNPs had
an influence on ABCA1 promoter transcriptional activity and
whether the coding SNPs had an effect on ABCA1 function
in mediating cellular cholesterol efflux.
RESULTS
The ABCA1 gene had been re-sequenced using DNA samples
from individuals of European ancestry in previous studies by
other researchers (14,15), which identified a number of
SNPs. In this study, we focused on common SNPs in the pro-
moter and common non-synonymous SNPs in the coding
region, using the conventional definition of common SNPs
as those which have a minor allele frequency .0.05 (17).
We genotyped a group of British European CAD patients
(n ¼ 1164, demographic and clinical characteristics summar-
ized in Table 1) for the SNPs depicted in Figure 1, which
had previously been shown to have a minor allele frequency
.0.05 in Europeans (10–15). The observed genotype distri-
butions of all SNPs were consistent with Hardy–Weinberg
equilibrium, and the allele frequencies were similar to those
reported in other population samples of European ancestry
(10–15). As in other studies (14,15), we detected strong
linkage disequilibrium (LD) among the promoter SNPs, sub-
stantial LD among some of the coding SNPs, but little LD
between promoter SNPs and coding SNPs (Table 2). There-
fore, separate haplotype analyses were carried out for the pro-
moter SNPs and the coding SNPs, as in other studies (14,15).
ABCA1 single nucleotide polymorphisms and age of
symptom onset in coronary artery disease patients
Mean age of symptom onset was 2.82 years higher in patients
who were homozygous for the C allele of the ABCA1 promoter
2407G.C SNP than in those who were homozygous for the
2407G allele, and intermediate in heterozygotes [mean
(SD) ¼ 61.54 (9.72), 59.79 (9.59) and 58.72 (9.99) years for
the C/C, C/G and G/G genotypes, respectively; P ¼ 0.002,
Table 3]. The association remained significant after adjusting
for gender, smoking, body mass index, cholesterol, triglycer-
ides, lipid-lowering treatment, hypertension, type 1 diabetes,
type 2 diabetes and family history of CAD (P ¼ 0.004).
Gender ratio, percentage of smokers, body mass index, choles-
terol and triglyceride levels, hypertension, type 2 diabetes
mellitus and family history of CAD did not significantly
differ among the different 2407G.C genotype groups. The
percentage of type 1 diabetics was found to be higher
among subjects of the C/C genotype (6.3%) than among
those of the G/C or G/G genotype (2.4 and 2.2%, respectively)
(P ¼ 0.01). The association between 2407G.C and age of
CAD onset remained significant after excluding subjects
with type 1 diabetes (n ¼ 36) and adjusting for the other vari-
ables mentioned above (P ¼ 0.003).
Some weaker relationships between CAD symptom onset
age and 2278G.C (P ¼ 0.007), 2565C.T (P ¼ 0.01),
2940T.G (P ¼ 0.03) and 21395C.T (P ¼ 0.04) were
observed (Table 3), however, they failed to reach significance
after multiple testing correction with the use of the SNPSpD
method (18) which indicated that a significance threshold of
P , 0.0042 is required taking into account the number of
SNPs examined and LD between the SNPs.
No significant association was detected between age of
onset and the other promoter SNPs or the coding region
SNPs examined, although it was noted that onset age
in 825I/825I homozygotes was 2.71 years higher than that in
825V/825I heterozygotes and 3.76 years higher than that in
825V/825V homozygotes [mean (SD) ¼ 63.46 (9.07), 60.75
(9.52) and 59.70 (9.86) years, respectively; P . 0.05;
Table 3] and that onset age in 883M/883M homozygotes
was 3.02 years higher than that in 883I/883M heterozygotes
and 1.74 years higher than that in 883I/883I homozygotes
[mean age (SD) ¼ 62.12 (6.36), 59.10 (9.65) and 60.38
(9.66) years, respectively; P . 0.05; Table 3].
ABCA1 haplotypes and age of symptom onset in
coronary artery disease patients
There were six major haplotypes (each having a frequency
.0.05) deriving from the 15 promoter SNPs studied, i.e. T-1801
A-1652G-1506T-1395G-1252C-1217Ins-1034T-940G-803C-565G-407C-302
G-278C-99C-14, C-1801G-1652G-1506C-1395A-1252C-1217Ins-1034
Table 1. Characteristics of subjects
Mean (SD) or %
Age of symptom onset (years) 59.77 (9.83)
Male gender 76.3%
Current and previous smokers 74.6%
Body mass index (kg/m2) 27.54 (4.27)
Cholesterol (mmol/L) 5.11 (1.02)
HDL cholesterol (mmol/L) 1.25 (0.31)
Triglycerides (mmol/L) 1.86 (1.22)
Hypertension 45.0%
Type 1 diabetes 3.1%
Type 2 diabetes 10.2%
Family history of CAD 48.5%
Data shown are mean (SD) for continuous variables or % for categorical
variables.
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T-940G-803C-565G-407C-302G-278G-99C-14, C-1801A-1652C-1506C-1395
G-1252C-1217Del-1034G-940G-803T-565C-407T-302C-278G-99T-14,
C-1801G-1652G-1506C-1395G-1252C-1217Ins-1034G-940G-803T-565
C-407C-302C-278G-99T-14, C-1801G-1652G-1506C-1395G-1252T-1217
Ins-1034G-940G-803T-565C-407C-302C-278G-99C-14, T-1801A-1652
G-1506T-1395G-1252C-1217Ins-1034T-940A-803C-565G-407C-302G-278
G-99C-14.These haplotypes couldbe tagged by a set of fiveSNPs:
2803G.A,2407G.C,2302C.T,299G.Cand214C.T,
identified using theSNPtagger program (19).Ahaplotype analy-
sis of these five taggingSNPs in relation to age ofCADsymptom
onset showed that theG-803-C-407-C-302-G-99-C-14 haplotypewas
associated with higher onset age (P ¼ 0.003, Table 4), and the
association remained significant (P ¼ 0.002) after adjusting for
gender, body mass index, smoking, cholesterol, triglycerides,
lipid-lowering treatment, hypertension, type 1 diabetes, type 2
diabetes and family history of CAD. G-803-C-407-C-302-
G-99-C-14 haplotype carriers have slightly higher percentages of
type 1 diabetic subjects (8.8% in subjects with two copies,
3.6% in those with one copy, 2.3% in those with zero copy, of
the G-803-C-407-C-302-G-99-C-14 haplotype, P ¼ 0.057). The
association between the G-803-C-407-C-302-G-99-C-14 haplotype
and increased age of CAD onset remained significant
(P ¼ 0.002) after excluding type 1 diabetic subjects. There was
no difference among the different haplotypes in gender ratio,
percentage of smokers, body mass index, cholesterol levels,
triglyceride levels, hypertension, type 2 diabetes mellitus and
family history of CAD. A weaker relationship between
increased CAD onset age and another haplotype, i.e.
G-803-C-407-T-302-G-99-T-14, was also observed (P ¼ 0.006 after
adjusting for the covariates mentioned above, Table 4).
A previous study showed that the ABCA1 promoter region up
to nucleotide position 2580 is essential in regulating ABCA1
transcription (20). An analysis of haplotypes derived from the
SNPs in this region (i.e. 2565C.T, 2407G.C, 2302C.T,
2278G.C, 299G.C and 214C.T) showed that there were
five major haplotypes (each with a frequency of .0.05,
Table 4), and that theT-565-C-407-C-302-C-278-G-99-C-14 haplotype
was associated with higher age of CAD onset (P ¼ 0.002,
Table 4). The association remained significant after adjustment
for gender, bodymass index, smoking, cholesterol, triglycerides,
lipid-lowering treatment, hypertension, type 1 diabetes, type 2
diabetes and family history of CAD (P ¼ 0.003). A weaker
relationship between the T-565-C-407-T-302-C-278-G-99-T-14 and
increased CAD onset age was also detected (P ¼ 0.01 after
adjusting for covariates, Table 4).
ABCA1 single nucleotide polymorphisms and
coronary stenosis
Patients of the G/G or G/C genotype of the 2407G.C SNP
had significant coronary stenosis (.75%) at a younger age
than those of the C/C genotype (P ¼ 0.003; Fig. 2A). A
haplotype analysis of the promoter-tagging SNPs described
above showed that compared with patients of the
G-803-C-407-C-302-G-99-C-14 or G-803-C-407-T-302-G-99-T-14 hap-
lotype, those of other haplotypes had significant coronary
stenosis at a younger age (P ¼ 0.02; Fig. 2B). Similarly, a
haplotype analysis of the six proximal promoter SNPs
showed that compared with patients of the T-565-C-407-
C-302-C-278-G-99-C-14 or T-565-C-407-T-302-C-278-G-99-T-14
haplotype, those of other haplotypes had significant coronary
stenosis at a younger age (P ¼ 0.01; Fig. 2C).
ABCA1 single nucleotide polymorphisms and plasma
high-density lipoprotein level
825I/825I homozygotes had higher mean HDL level than
825V/825I heterozygotes who in turn had higher mean HDL
level than 825V/825V homozygotes [mean (SD) ¼ 1.54
(0.07), 1.34 (0.31) and 1.23 (0.30) mmol/l, respectively;
P ¼ 0.01; Table 5]. Comparing different genotypes of the
I883M polymorphism, 883M/883M homozygotes and 883I/
883M heterozygotes had higher mean HDL level than 883I/
883I homozygotes [mean (SD) ¼ 1.34 (0.34), 1.39 (0.36)
and 1.20 (0.27) mmol/l, respectively; P ¼ 0.0004; Table 5].
The relationships were still observed after adjusting for age,
gender, smoking, body mass index, hypertension, type 1 dia-
betes, type 2 diabetes and family history of CAD (P ¼ 0.048
for V825I and P ¼ 0.001 for I883M). Gender ratio, percentage
of smokers, body mass index, total cholesterol and triglyceride
levels, hypertension, type 1 and type 2 diabetes and family
history of CAD did not significantly differ among the different
genotypes of the V825I and I883M SNPs. No significant
association was observed between HDL level and the other
SNPs studied.
ABCA1 promoter activity assays
To investigate whether there were differences in promoter
activity between the different ABCA1 promoter haplotypes,
transient transfection and luciferase reporter assays were
carried out. The experiments showed that compared with the
most common haplotype C-565-G-407-C-302-G-278-G-99-C-14,
the T-565-C-407-C-302-C-278-G-99-C-14 haplotype had approxi-
mately 2-fold higher promoter activity, and the
T-565-C-407-C-302-C-278-G-99-T-14 approximately 1.2-fold
higher promoter activity (Fig. 3A). The promoter activity of
all ABCA1 haplotypes examined was significantly increased
when the transfected cells were treated with
22(R)-hydroxycholesterol and 9-cis-retinoic acid which had
been shown to upregulate ABCA1 transcription (21–23)
(Fig. 3B). An increase in promoter activity of all the
Figure 1. Schematic diagram of the locations of SNPs studied in the ABCA1 gene. Drawing not to scale.
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ABCA1 haplotypes was also observed when transfected cells
were treated with 8-bromoadenosine-30,50-cyclic monophos-
phate (8-br-cAMP) which had also been demonstrated to
increase ABCA1 expression (Fig. 3C) (21). In 22(R)-hydroxy-
cholesterol and 9-cis-retinoic acid treated cells and in
8-br-cAMP treated cells, the promoter activity of T-565-C-407-
C-302-C-278-G-99-C-14 was over 2-fold higher, T-565-C-407-T-302-
C-278-G-99-T-14 over 1.5-fold higher and T-565-C-407-C-302-C-278-
G-99-T-14 approximately 1.5-fold higher, than the most
common haplotype C-565-G-407- C-302-G-278-G-99-C-14 (Fig. 3B
and C).
Functional analysis of ABCA1 coding single nucleotide
polymorphisms
We also investigated whether any of the common non-
synonymous coding SNPs studied had an effect on the
activity of ABCA1 in facilitating cholesterol efflux, by trans-
fecting cells with plasmids expressing the different ABCA1
alleles and then determining the rates of cholesterol efflux
from the cells. The assays showed that cells expressing the
825I variant had higher rate of apoAI-mediated cholesterol
efflux than cells expressing the wild-type (825V) ABCA1
(P ¼ 0.003; Fig. 4). There was also a trend towards
increased rate of apoAI-mediated cholesterol efflux in cells
expressing the 883M variant compared with cells expressing
the wild-type (883I). Cells expressing the 219K or 1587K
variants had similar rates of apoAI-mediated cholesterol
efflux to those expressing the wild-type (219R and 1587R)
(Fig. 4). As expected, compared with the rate of cholesterol
efflux in cells transfected with the plasmid expressing the
wild-type ABCA1, the rates of cholesterol efflux were sig-
nificantly lower in untransfected cells and in cells transfected
with the plasmid expressing the ABCA1 (V1704D and
L1379F) mutant which had previously been shown to
result in complete loss of ABCA1 function (24)
(P , 0.001; Fig. 4).
DISCUSSION
In this study of a large group of CAD patients, we found an
association between age of symptom onset and the ABCA1
promoter 2407G.C SNP. Age of symptom onset was
2.82 years higher in 2407C allele homozygotes than in
2407G allele homozygotes, and intermediate in hetero-
zygotes, suggesting an allele-dose effect. The influence of
this common SNP on age of symptom onset is moderate, com-
pared with the effects of rare, severe loss-of-function ABCA1
mutations that cause Tangier disease and that can lead to CAD
two decades earlier in homozygotes and one decade earlier in
heterozygotes (8,9). However, the high frequency of the
2407G.C SNP (the C/C and G/C genotypes were 20 and
48%, respectively, in our patient group) makes it a potentially
important genetic factor in many CAD patients in the popu-
lation. In agreement with results of the individual SNP ana-
lyses, haplotype analyses showed that patients carrying
common promoter haplotypes bearing the 2407C allele had
higher age of symptom onset. In addition, we found that
2407G allele homozygotes had significant coronary arteryT
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stenosis at a younger age than heterozygotes who in turn had
significant coronary stenosis at a younger age than 2407C
allele homozygotes. In vitro assays showed that the 2407C
allele-bearing promoter haplotypes had higher promoter
activity than the promoter haplotypes with the 2407G
allele. The association of the 2407C allele with higher age
of symptom onset in CAD patients and a delay in developing
significant coronary stenosis together with the higher promoter
activity of the 2407C allele suggest a protective effect of this
allele potentially through increased ABCA1 expression. In
this study, we also found weak relationships of age of
symptom onset with the 2278G.C, 2565C.T, 2940T.G
and 21395C.T SNPs which are in strong LD with the
2407G.C SNP, but the relationship of the 2278G.C,
2565C.T, 2940T.G and 21395C.T SNPs with age of
symptom onset did not reach statistical significance after
correction for multiple testing.
We noted that age of symptom onset in 825I/825I homo-
zygotes was 2.71 years higher than that in 825V/825I hetero-
zygotes and 3.76 years higher than that in 825V/825V
homozygotes and that symptom onset in 883M/883M homo-
zygotes was 3.02 years later than that in 883I/883M heterozy-
gotes and 1.74 years later than that in 883I/883I homozygotes,
although the differences were not statistically significant. In
addition, we observed a relationship of the 825I and 883M
alleles with higher HDL levels. The 825I allele has previously
been reported to be associated with higher plasma HDL level
in an investigation of over 9000 individuals from the Danish
general population (15), and the 883M allele has been
associated with higher plasma HDL level in studies of
European Americans (25), African Americans (25), Japanese
(26) and Inuit Canadians (10). The V825I and I883M SNPs
were found to be in strong LD in our sample and other Euro-
pean populations (14,15). In the in vitro assays, we found that
the rate of cholesterol efflux in cells expressing the 825I
variant was higher than in cells expressing the ABCA1 wild-
type (825V), indicating a potential effect of V825I on
ABCA1 function in facilitating cellular cholesterol efflux,
which could potentially explain its association with HDL
level. The assays also showed a higher rate of cholesterol
efflux in cells expressing the 883M variant than cells expres-
sing the wild-type (883I), although the difference did not
reach statistical significance.
The R1587K SNP was also found to be associated with
plasma HDL levels in the study of the Danish population
(15) mentioned above and in a study in Dutch men (11),
with the 1587K allele associating with lower HDL levels. In
addition, a study of individuals from Scotland and Northern
Ireland showed that the 1587K allele was associated with
lower plasma levels of apoAI, the major apolipoprotein in
HDL (14). In the present study, we observed a lower mean
HDL level in 1587K allele homozygotes but it was not statisti-
cally significant. In the in vitro assays, there was no significant
difference in cholesterol efflux between cells expressing the
1587K variant and the wild-type ABCA1 (1587R). It is plaus-
ible that the relationship of this SNP with plasma HDL level
might have arisen from its LD with other SNPs such as
V825I. In the studies mentioned above (10,11,15,26), no
Table 3. Age (years) of CAD symptom onset according to ABCA1 genotypes
Polymorphism Genotype Mean (SD), n P-value Polymorphism Genotype Mean (SD), n P-value
21801C.T (rs2487046)
C/C 60.48 (9.83), 353
0.09 2565C.T (rs2422493)
C/C 58.95 (9.92), 318
0.01C/T 59.58 (9.74), 463 C/T 59.84 (9.59), 496
T/T 59.03 (9.68), 168 T/T 61.13 (10.1), 214
21652A.G (rs10124728)
A/A 59.45 (9.96), 389
0.29 2407G.C (rs2246293)
G/G 58.72 (9.99), 296
0.002A/G 59.59 (9.62), 488 G/C 59.79 (9.59), 458
G/G 60.74 (10.0), 119 C/C 61.54 (9.72), 191
21506G.C (rs2487047)
G/G 59.51 (9.74), 609
0.12 2302C.T (rs2246298)
C/C 59.45 (9.82), 619
0.15G/C 60.26 (9.84), 343 C/T 60.38 (9.86), 276
C/C 61.54 (10.41), 41 T/T 60.90 (10.5), 33
21395C.T (rs2487048)
C/C 60.52 (9.90), 357
0.04 2278G.C (rs1800976)
G/G 58.94 (9.82), 313
0.007C/T 59.67 (9.66), 462 G/C 59.70 (9.67), 463
T/T 58.72 (9.79), 180 C/C 61.39 (10.3), 204
21252G. A
G/G 59.94 (9.79), 708
0.57 299G.C (rs2740483)
G/G 60.41 (9.90), 505
0.12G/A 59.80 (9.88), 180 G/C 59.41 (9.68), 363
A/A 57.80 (8.82), 15 C/C 59.18 (9.35), 78
21217C.T (rs10991420)
C/C 59.47 (9.82), 769
0.05 214C.T (rs1800977)
C/C 59.80 (9.69), 460
0.54C/T 61.11 (9.48), 209 C/T 59.74 (9.80), 401
T/T 59.82 (11.39), 11 T/T 60.68 (10.5), 113
21034ATins/del (rs34669957)
AT/AT 59.63 (9.71), 621
0.37 R219K (rs2230806)
R/R 60.07 (9.94), 503
0.52AT/2 60.14 (9.73), 350 R/K 59.82 (9.84), 392
2/2 60.49 (11.13), 43 K/K 59.33 (8.81), 78
2940T.G (rs2980083)
T/T 59.11 (9.51), 273
0.03 V825I (rs28587567)
V/V 59.70 (9.86), 866
0.24T/G 59.85 (9.68), 430 V/I 60.75 (9.52), 100
G/G 61.07 (9.86), 200 I/I 63.46 (9.07), 4
2803G.A (rs10991419)
G/G 59.83 (9.74), 812
0.79 I883M (rs4149313)
I/I 60.38 (9.66), 644
0.23G/A 59.73 (9.91), 192 I/M 59.10 (9.65), 217
A/A 58.94 (10.85), 14 M/M 62.12 (6.36), 19
R1587K (rs2230808)
R/R 60.23 (9.95), 496
0.30R/K 58.90 (9.50), 301
K/K 60.93 (9.12), 41
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association was detected between the R219K SNP and plasma
level of HDL. In line with these studies, we found neither an
association between this SNP and plasma HDL level nor an
effect of this SNP on ABCA1 function in mediating cellular
cholesterol efflux.
In this study we detected an association between the
2407G.C SNP and age of symptom onset in the CAD
patients without an association between this SNP with
plasma HDL level. This could potentially be due to inadequate
statistical power in the test of genotypic effects on HDL levels,
as data on HDL level were available only for 276 subjects who
were not on lipid-lowering medication. A power calculation
suggested that with this sample size and the 2407G.C
SNP minor allele frequency being 0.44, the minimal effect
size detectable in this study was 0.033 mmol/l in HDL level
with 0.80 power and at a ¼ 0.0042, and was 0.025 mmol/l
at a ¼ 0.05. Thus, if the 2407G.C SNP has a smaller
effect than the abovementioned minimal effect size, it would
be unlikely to be detected in this study. An alternative expla-
nation is that ABCA1 genotypes can influence CAD pheno-
types without displaying a significant effect on plasma HDL
levels. Several previous studies have encountered a situation
where ABCA1 SNPs are associated with CAD in the absence
of an association with plasma HDL level (11–13). It has
been suggested that subtle changes in cellular cholesterol
efflux in the vascular wall could have an impact on atherogen-
esis, without an apparent effect on plasma HDL level (11,13).
In contrast with the traditional ‘reverse cholesterol transport’
theory in which HDL is thought to originate from peripheral
tissues and subsequently transferred to the liver (27), recent
studies have revealed that the major source of plasma HDL is
actually the liver (28–32), and that cholesterol efflux from
macrophages accounts for only a very small portion of the
total plasma HDL but nevertheless is very important with
regard to the development of atherosclerosis (28,33,34).
It has been demonstrated that the functional effects of SNPs
in the promoter of the interleukin-1B gene are dependent on
haplotype context, i.e. a particular allele of a SNP can
reduce promoter activity in the context of one haplotype but
increase promoter activity in the context of another haplotype
(35). Such functional interactions between promoter SNPs
have also been detected in the genes for interleukin-6 and cho-
lesteryl ester transfer protein (36,37). We previously observed
that in the C-407-C-302-C-278-G-99-C-14 haplotype background,
the 2565T allele (i.e. T-565-C-407-C-302-C-278-G-99-C-14) had
a lower promoter activity than the 2565C allele (i.e.
C-565-C-407-C-302-C-278-G-99-C-14) (16). We subsequently
found that in the G-407-C-302-G-278-G-99-C-14 haplotype back-
ground, the 2565T allele (i.e. T-565-G-407-C-302-G-278-
G-99-C-14) had higher promoter activity than the 2565C
allele (i.e. C-565-G-407-C-302-G-278-G-99-C-14). This suggests
that the effect of the ABCA1 2565C.T SNP is also depen-
dent on the context of the other ABCA1 promoter SNPs.
The most relevant comparison, however, would be the
T-565-C-407-C-302-C-278-G-99-C-14 haplotype versus the
C-565-G-407-C-302-G-278-G-99-C-14 haplotype as shown in
Figure 1, since these two haplotypes have high frequencies
(0.277 and 0.105, respectively, in this study) whereas the
C-565-C-407-C-302-C-278-G-99-C-14 and T-565-G-407-C-302-G-278-
G-99-C-14 are extremely rare (frequencies 0.0007 and 0.001,T
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respectively). The abovementioned findings in several
different genes (interleukin-1B, interleukin-6, cholesteryl
ester transfer protein and ABCA1) indicate that it is important
to examine haplotypes rather than an individual SNP in func-
tional analyses of promoter SNPs.
In summary, the results of our study indicate an influence of
common functional polymorphism in the ABCA1 gene on age
of symptom onset in CAD patients. The data provide new evi-
dence supporting the notion that genetic variations in ABCA1
contribute to inter-individual differences in CAD predisposi-
tion and progression in the general population.
MATERIALS AND METHODS
Subjects
We studied a group (n ¼ 1164) of British European patients
with angiographically confirmed CAD, recruited from
Table 5. Plasma HDL levels (mmol/L) according to ABCA1 genotypes
Polymorphism Genotype Mean (SD), n P-value Polymorphism Genotype Mean (SD), n P-value
21801C.T (rs2487046)
C/C 1.26 (0.31), 93
0.88 2565C.T (rs2422493)
C/C 1.25 (0.32), 81
0.78C/T 1.23 (0.31), 122 C/T 1.24 (0.30), 137
T/T 1.29 (0.33), 40 T/T 1.23 (0.28), 54
21652A.G (rs10124728)
A/A 1.22 (0.29), 99
0.37 2407G.C (rs2246293)
G/G 1.24 (0.32), 76
0.80A/G 1.25 (0.31), 131 G/C 1.23 (0.30), 123
G/G 1.29 (0.35), 30 C/C 1.24 (0.27), 52
21506G.C (rs2487047)
G/G 1.26 (0.33), 156
0.47 2302C.T (rs2246298)
C/C 1.26 (0.32), 165
0.67G/C 1.21 (0.28), 90 C/T 1.21 (0.27), 68
C/C 1.24 (0.29), 14 T/T 1.27 (0.26), 13
21395C.T (rs2487048)
C/C 1.26 (0.31), 96
0.83 2278G.C (rs1800976)
G/G 1.25 (0.32), 80
0.79C/T 1.22 (0.29), 115 G/C 1.24 (0.30), 126
T/T 1.26 (0.32), 45 C/C 1.23 (0.28), 51
21252G.A
G/G 1.23 (0.29), 193
0.13 299G.C (rs2740483)
G/G 1.25 (0.29), 139
0.83G/A 1.27 (0.29), 44 G/C 1.23 (0.31), 93
A/A 1.27 (0.34), 7 C/C 1.30 (0.28), 21
21217C.T (rs10991420)
C/C 1.25 (0.32), 202
0.64 214C.T (rs1800977)
C/C 1.25 (0.31), 126
0.59C/T 1.23 (0.28), 56 C/T 1.25 (0.32), 99
T/T 0.97 (2), 1 T/T 1.20 (0.23), 30
21034ATins/del (rs34669957)
AT/AT 1.27 (0.33), 157
0.36 R219K (rs2230806)
R/R 1.26 (0.30), 129
0.58AT/2 1.21 (0.26), 89 R/K 1.23 (0.30), 104
2/2 1.24 (0.29), 14 K/K 1.25 (0.34), 18
2940T.G (rs2980083)
T/T 1.24 (0.32), 70
0.77 V825I (rs28587567)
V/V 1.23 (0.30), 232
0.01T/G 1.24 (0.31), 117 V/I 1.34 (0.31), 26
G/G 1.22 (0.29), 53 I/I 1.54 (0.07), 3
2803G.A (rs10991419)
G/G 1.26 (0.31), 208
0.40 I883M (rs4149313)
I/I 1.20 (0.27), 172
0.0004G/A 1.20 (0.28), 51 I/M 1.39 (0.36), 56
A/A 1.32 (0.47), 4 M/M 1.34 (0.34), 9
R1587K (rs2230808)
R/R 1.27 (0.31), 142
0.39R/K 1.24 (0.30), 84
K/K 1.18 (0.20), 9
Figure 2. Cumulative hazards of significant (.75%) stenosis in at least one coronary artery over age according to 2402G.C genotypes (A), promoter-tagging
SNPs haplotypes (carriage of G-803-C-407-T-302-G-99-T-14 or G-803-C-407-C-302-G-99-C-14) (B) and proximal promoter SNPs haplotypes (carriage of
T-565-C-407-T-302-C-278-G-99-T-14 or T-565-C-407-C-302-C-278-G-99-C-14) (C).
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consecutive patients undertaking diagnostic or interventional
angiography in Southampton General Hospital from May
1999 to March 2002, as previously described (38). The main
demographic and clinical characteristics of the patients are
summarized in Table 1. Age of symptom onset refers to the
age of first episode of angina pectoris or myocardial infarction.
Data on plasma HDL level were available for 276 subjects
who were not on lipid-lowering medication. The study was
approved by the Local Ethics Committee and all subjects
gave written consent.
Single nucleotide polymorphism selection and
determination of genotypes
The subjects of this study were genotyped for 15 common SNPs
in the proximal promoter region, i.e. 21801C.T (rs2487046),
21652A.G (rs10124728), 21506G.C (rs2487047),
21395C.T (rs2487048), 21252G.A (rs number unavailable),
21217C.T (rs10991420), 21034A Tins/del (rs34669957),
2940T.G (rs2980083), 2803G.A (rs10991419), 2565C.T
(rs2422493), 2407G.C (rs2246293), 2302C.T (rs2246298),
2278G.C (rs1800976), 299G.C (rs2740483) and 214C.T
(rs1800977), respectively, and four common non-synonymous
SNPs, i.e. R219K (rs2230806), V825I (rs28587567), I883M
(rs4149313) and R1587K (rs2230808) (Fig. 1). These SNPs had
previously been shown to have a minor allele frequency.0.05 in
Europeans (10–15). The genotyping methods and PCR primers
are summarized in Supplementary Material, Table S1.
Promoter activity assays
Transient transfection and reporter assays were performed to
investigate whether there were differences in promoter activity
among the different ABCA1 haplotypes derived from the six
proximal promoter SNPs. For each haplotype, the correspond-
ing ABCA1 promoter (from position 2588 bp to þ21 bp rela-
tive to the transcriptional start site) was generated by PCR
using genomic DNA as template and then inserted into a
Figure 3. Relative promoter activity of different ABCA1 haplotypes in unstimulated cells (A), cells treated with 22(R)-hydroxycholesterol and 9-cis-retinoic acid
(B) and cells treated with 8-bromoadenosine-30,50-cyclic monophosphate (C). Note. different scales shown in the three charts. P , 0.01 compared with the
wild-type haplotype C-G-C-G-G-C; P, 0.05 compared with the wild-type haplotype C-G-C-G-G-C.
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plasmid (pGL3-basic vector, Promega) containing a firefly
luciferase reporter gene. All constructs were verified by
DNA sequencing. RAW264.7 cells were transfected with
each of the above constructs with the use of FuGENE 6
transfection reagent (Roche Diagnostics). A plasmid
(pRL-TK, Promega) containing a renilla luciferase gene
under the control of a thymidine kinase promoter, was
co-transferred into the cells to serve as a reference for trans-
fection efficiency. Transfected cells were untreated or treated
with 22(R)-hydroxycholesterol (20 mM) and 9-cis-retinoic
acid (10 mM) for 24 h or treated with 8-bromoadenosine
30,50-cyclic monophosphate (0.3 mM) for 24 h. At 36 h after
transfection, the cells were lysed, and the activities of firefly
luciferase and renilla luciferase in the lysates were measured
with the use of a dual-luciferase assay kit (Promega).
ABCA1 gene promoter activity was determined according to
the ratio of firefly luciferase activity to renilla luciferase
activity. Three independent experiments were performed. In
each experiment, transfection and luciferase assays were
carried out in duplicate for each construct.
Cholesterol efflux assays
Using a previously constructed plasmid expressing full-length
human wild-type ABCA1 cDNA (24) as a template, plasmids
expressing the ABCA1 219K, 825I, 883M and 1587K variants,
respectively, were generated with the use of the site-directed
mutagenesis method described by Scott et al. (39). All
plasmid constructs were verified by DNA sequencing. Cul-
tured COS-7 cells were transfected with each of the above
plasmids or a plasmid expressing an ABCA1 mutant
(V1704D and L1379F) described in Albrecht et al. (24).
Transfection was carried out with the use of FuGENE 6
transfection reagent (Roche Diagnostics). At 24 h post-
transfection, transfection efficiency was determined by fluor-
escence microscopy and fluorescence-activated cell sorting.
Cholesterol efflux assays were performed using a method
described by Gelissen et al. (40) with minor modifications.
In brief, transfected cells were incubated with [3H] cholesterol
(Moravek Biochemicals, USA) for 48 h, washed and
equilibrated for 18 h in serum-free medium. The cells were
then incubated in efflux medium with or without 20 mg/ml
apolipoprotein AI (apoAI, Sigma) as an acceptor. Six hours
later, efflux media were removed and cells were washed and
then dissolved in 0.1 M NaOH solution. Radioactivity (disinte-
grations per minute) was measured in the medium and in the
cell extract. Three independent experiments were performed,
in each of which transfection and cholesterol efflux assay
were carried out in triplicate for each construct. The rate of
cholesterol efflux was calculated using the following
formula: radioactivity in medium/(radioactivity in mediumþ
radioactivity in cell extract). The values (apoA1-mediated
efflux minus mean of unstimulated cells) for cells transfected
to express the 219K, 825I, 883M or 1587K variant or
co-express 825I and 883M were compared with the mean of
values (apoA1-mediated efflux minus mean of unstimulated
cells) for cells transfected with the plasmid expressing
ABCA1 wild-type.
Statistical analyses
Allele and genotype frequencies were calculated by gene
counting. x2 test with 1 degree of freedom and a ¼ 0.05
level was used to examine whether the observed genotype dis-
tributions deviated from Hardy–Weinberg equilibrium. LD
coefficient (D0), haplotypes and haplotype frequencies were
determined with the use of the THESIAS and PHASE
(version 2.1) programs (41–43).
The SNPSpD method by Nyholt (18) was used to calculate
the significance threshold required in this study to keep type I
error rate at 5% accounting for the number of SNPs tested and
LD between the SNPs, which gave a significant threshold of
0.0042. Single SNP association analyses of age of CAD
symptom onset and plasma HDL level were performed by
linear regression using an additive genetic model at each
SNP. Using the stepwise regression procedure, the relationship
between genotype and age of CAD onset was adjusted for
gender, smoking, body mass index, cholesterol, triglycerides,
lipid-lowering treatment, hypertension, type 1 diabetes, type 2
diabetes and family history of CAD. Using the same pro-
cedure, the relationship of genotypes with HDL level was
adjusted for age, gender, smoking, body mass index, hyperten-
sion, type 1 diabetes, type 2 diabetes and family history of
CAD. Minimum effect sizes detectable in this study were cal-
culated post hoc by approximating the linear model by a score
test for which the non-centrality parameter is available (44).
Haplotype-tagging SNPs were identified with the use of the
SNPtagger computer program developed by Ke and Cardon
(19). Haplotype effects on age of CAD symptom onset and
plasma HDL level were tested with the use of the THESIAS
program (41). The Kaplan–Meier procedure with Breslow
test was used to examine whether there was a relationship
between the presence of significant coronary stenosis
(.75% stenosis in at least one coronary artery) and age at
the time of coronary angiography and whether this relation-
ship was influenced by ABCA1 genotypes and haplotypes.
Figure 4. Results of apoAI-mediated cholesterol efflux assay of ABCA1
coding SNPs. Asterisk indicates P ¼ 0.003 comparing the rate of apoAI-
mediated cholesterol efflux in cells transfected with the plasmid expressing
the 825I variant with that in cells transfected with the plasmid expressing
the wild-type ABCA1 (825V). 825Iþ 833M refers to cells co-transfected
with the 825I and 883M plasmids. K.O. refers to an ABCA1 (V1704D and
L1379F) mutant which had previously been shown to result in complete
loss of ABCA1 function (24).
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In the luciferase assays and cholesterol efflux assays, differ-
ences in luciferase activity between haplotypes and in choles-
terol efflux rate between cells transfected with different
constructs were assessed by ANOVA and t-test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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